Search

CROI Cure Reflections Video Series

Produced by PAVE (Pediatric Adolescent Virus Elimination), this weekly series of four videos provides HIV cure-related takeaways from CROI 2026.

Global Health Watch: PEPFAR Data, Latest in Health Deals, Lawmakers Oppose Redirected Global Health Funding, Pushback on Expanded Gag Rule

On the heels of the recent PEPFAR data release, a New York Times article this week serves as an illustration of the consequences of the US policy decisions on lives. It shows what the policy shifts, funding disruptions, and data gaps covered in this issue, look like in Zambia: strained clinics, interrupted HIV services, and uncertainty for patients and providers relying on PEPFAR.

Accelerating the Health Equity Impact of Interventions for Infectious Diseases in Africa

Attending INTEREST 2026? Resources to Support Your Participation

INTEREST will take place 12-15 May in Tanzania, covering new advances in HIV prevention, treatment, cure, and vaccine R&D; implementation science; and how science is being translated into impact. AVAC has compiled resources and highlights.

Uganda Key Populations Consortium Conversation on LEN

AVAC Infographics for INTEREST 2026

For those presenting at INTEREST, AVAC’s latest infographics on HIV R&D and the delivery pipeline, the current landscape of prevention options are available in an easy-to-use slide format—including lenacapavir for HIV PrEP volume commitments, and the impact of US funding cuts with new data from PEPFAR.

EXPrESSIVE Phase III Program Countries of MK-8527

Seventeen countries are hosting sites for the Phase 3 efficacy trials of a monthly PrEP pill, MK-8527, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase 3 trials at IAS 2025 in Kigali. MK-8527 was found to be safe and well-tolerated in Phase 2 clinical trials.

What the Latest PEPFAR Data Reveal and Why It Matters

Newly released data from the President’s Emergency Plan for AIDS Relief (PEPFAR) were meant to reassure, but a deeper look tells a more concerning story. Independent reviews and analyses of the data show consistent declines across testing, diagnoses and prevention. See the AVAC resources that put this all into context.

Data Don’t Lie, But the Story is Distorted

For more than two decades, PEPFAR has been widely recognized as one of the most effective global health programs that, with consistent bipartisan support, has weathered global disruptions and crises from Ebola to COVID-19. Today, PEPFAR’s legacy is facing a different kind of test: not a biological threat, but a political one.

Planting Seeds in These Times: Stories of Resistance and Possibility for the HIV Movement